Qureator Organ-on-Chip Breakthrough Marks Milestone Under FDA Modernization Act 2.0 | FDA approves IND based on human ...

The number of biopharma M&A deals announced so far this year is higher than the yearly average for the last 15 years, while ...

With a $157 million series C funding round, Hemab Therapeutics is looking to infuse innovation into the treatment landscape ...

MapLight Therapeutics is heading to the Nasdaq this morning via a $250 million IPO the biotech will use to advance its ...

Fresh from a European cancer conference that was all about antibody-drug conjugates (ADCs), GSK has turned to French biotech ...

| Build smarter healthcare apps, faster. See how clinical data repositories help developers unlock clinical data and drive ...

Intellia paused both trials after receiving a report of grade 4 liver enzymes and increased total bilirubin in a patient in ...

| Clinical development is undergoing a structural shift. Protocols are growing more complex, budgets are shrinking, and ...

The cell therapy field has long held a transformative ambition: to create "off-the-shelf" treatments that can reach not just ...

Zenas Biopharma’s lead autoimmune drug has been tied to a 95% reduction in a type of brain lesions over 12 weeks in a phase 2 multiple sclerosis (MS) study.  | Zenas Biopharma’s lead autoimmune drug ...

The Swiss pharma is paying $12 billion for Avidity Biosciences and its three late-stage antibody oligonucleotide conjugates.

The biotech’s phase 3 delivered the hoped-for second biomarker hit, reporting an 82% decline in serum creatine kinase after 12 months. BridgeBio’s base case and upside targets for the muscle damage ...